MannKind Corporation Reports 2023 Third Quarter Financial Results
November 07, 2023 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net...
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 06, 2023 06:15 ET
|
MannKind
INHALE-3 clinical trial in patients living with type 1 diabetes fully enrolled. Will evaluate inhaled insulin (with basal insulin) vs. usual care.
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
October 31, 2023 16:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial...
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
October 30, 2023 06:15 ET
|
MannKind
Patent covers compositions of clofazimine, and methods for treating lung infectionsDevelopment of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial...
MannKind Corporation Announces Participation at Upcoming Conferences
September 05, 2023 06:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2023 Second Quarter Financial Results
August 07, 2023 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues...
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
August 01, 2023 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
July 31, 2023 16:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial...
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
June 22, 2023 06:05 ET
|
MannKind
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Time-in-range during waking...
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
June 11, 2023 08:05 ET
|
MannKind
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides...